CUAMC
ABUS icon

China Universal Asset Management Company’s Arbutus Biopharma ABUS Stock Holding History

China Universal Asset Management Company’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151K Sell
31,438
-2,691
-8% -$11.8K 0.01% 378
2026
Q1 		$154K Buy
34,129
+2,790
+9% +$12.2K 0.01% 373
2025
Q4 		$151K Sell
31,339
-2,263
-7% -$10.2K 0.01% 373
2025
Q3 		$153K Sell
33,602
-4,865
-13% -$17.9K 0.01% 352
2025
Q2 		$119K Buy
38,467
+458
+1% +$1.52K 0.01% 350
2025
Q1 		$133K Sell
38,009
-2,170
-5% -$7.24K 0.01% 344
2024
Q4 		$131K Buy
40,179
+3,870
+11% +$14.2K 0.01% 366
2024
Q3 		$140K Buy
36,309
+14,138
+64% +$54.2K 0.02% 326
2024
Q2 		$68.5K Sell
22,171
-10,062
-31% -$30.2K 0.01% 331
2024
Q1 		$83.2K Buy
32,233
+12,833
+66% +$33.2K 0.01% 389
2023
Q4 		$48.5K Buy
19,400
+15,104
+352% +$29.6K 0.01% 373
2023
Q3 		$8.72K Buy
4,296
+2,119
+97% +$4.44K ﹤0.01% 356
2023
Q2 		$5.01K Buy
2,177
+57
+3% +$148 ﹤0.01% 367
2023
Q1 		$6.42K Buy
2,120
+530
+33% +$1.5K ﹤0.01% 342
2022
Q4 		$3.71K Buy
1,590
+186
+13% +$445 ﹤0.01% 332
2022
Q3 		$3K Buy
+1,404
New +$3.31K ﹤0.01% 315

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

China Universal Asset Management Company's ABUS Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Arbutus Biopharma (ABUS) stake by 7.9% in Q2 2026, selling an estimated $11.8K and leaving 31,438 shares worth $151K. The position accounts for 0.01% of the portfolio, ranked #378.

China Universal Asset Management Company first reported a position in ABUS in Q3 2022 and has held it in 16 quarters since. The position peaked at $154K in Q1 2026. 88 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • China Universal Asset Management Company held 31,438 shares of Arbutus Biopharma worth $151K as of Q2 2026.
  • China Universal Asset Management Company sold 2,691 Arbutus Biopharma shares in Q2 2026, an estimated $11.8K.
  • Arbutus Biopharma made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #378 holding.
  • China Universal Asset Management Company first reported a position in Arbutus Biopharma in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's Arbutus Biopharma position peaked at $154K in Q1 2026.
  • 88 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.